BOND-003: Clinical Implications for HR BCG-Unresponsive NMIBC Treatment

Opinion
Video

Gary D. Steinberg, MD explains the implications of the BOND-003 results for clinical practice in treating non-muscle-invasive bladder cancer (NMIBC), highlighting the potential benefits of novel immunotherapeutic options like cretostimogene grenadenorepvec as a bladder-sparing therapy for BCG-unresponsive high-risk NMIBC, and discusses how this treatment could fit into the NMIBC treatment landscape if approved.

Video content above is prompted by the following questions:

  • What could the results from BOND-003 mean for clinical practice in the treatment of patients with non-muscle-invasive bladder cancer (NMIBC)?
    • What type of patient could benefit from novel immunotherapeutic options (bladder sparing therapy) for BCG-unresponsive high-risk non-muscle-invasive bladder cancer?
    • If approved, how does cretostimogene fit into the treatment landscape for patients with NMBIC?
Recent Videos
Quitting smoking - male hand crushing cigarette | Image Credit: © mbruxelle - stock.adobe.com
Marc Bjurlin, DO, MSc, FACOS, answers a question during a Zoom video interview
Gary D. Steinberg, MD, an expert on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Gary D. Steinberg, MD, an expert on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Related Content
© 2024 MJH Life Sciences

All rights reserved.